$RLFTF Sounds like the FDA are liking the results
Post# of 653
"The FDA also granted an expanded access protocol for RLF-100 (aviptadil), from Geneva-based Relief Therapeutics Holdings AG and Radnor, Pa.-based Neurorx Inc., to those patients who are ineligible for enrollment in clinical trials" -
From the Article in Bio-World